Evidence map›Paper›PMID 26298207›Full record

ReviewEuropean urology2016

Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Johannes Schödel, Steffen Grampp, Eamonn R Maher, Holger Moch, Peter J Ratcliffe, Paul Russo, David R Mole

Open access · greenAbstract readReview
In one paragraph

Review in European urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 2 syntheses or guidelines pooled it, 409 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Expression of hypoxia-inducible factors in clear-cell renal cell carcinoma tumors of adults with and without obstructive sleep apnea.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  18. Article
  19. Article
  20. Article

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Johannes SchödelMedizinische Klinik 4 and Translational Research Center, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany. Electronic address: Johannes.Schoedel@uk-erlangen.de.
Steffen GramppMedizinische Klinik 4 and Translational Research Center, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
Eamonn R MaherDepartment of Medical Genetics, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK; Cambridge NIHR Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK.
Holger MochInstitute of Surgical Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Peter J RatcliffeHenry Wellcome Building for Molecular Physiology, University of Oxford, Oxford, UK.
Paul RussoDepartment of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, NY, NY, USA; Weill Medical College, Cornell University, Memorial Sloan Kettering Cancer Center, NY, NY, USA.
David R MoleHenry Wellcome Building for Molecular Physiology, University of Oxford, Oxford, UK.
Universitätsklinikum Erlangen · DEUniversity of Oxford · GBAddenbrooke's Hospital · GBCornell University · USUniversity of Zurich · CH

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cancer Research UK 16016Department of Health RP-2015-06-004NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

contextRenal cancer is a common urologic malignancy, and therapeutic options for metastatic disease are limited. Most clear cell renal cell carcinomas (ccRCC) are associated with loss of von Hippel-Lindau tumor suppressor (pVHL) function and deregulation of hypoxia pathways.

objectiveThis review summarizes recent evidence from genetic and biological studies showing that hypoxia and hypoxia-related pathways play critical roles in the development and progress of renal cancer. EVIDENCE ACQUISITION: We used a systematic search for articles using the keywords hypoxia, HIF, renal cancer, and VHL. EVIDENCE SYNTHESIS: Identification of the tumor suppressor pVHL has allowed the characterization of important ccRCC-associated pathways. pVHL targets α-subunits of hypoxia-inducible transcription factors (HIF) for proteasomal degradation. The two main HIF-α isoforms have opposing effects on RCC biology, possibly through distinct interactions with additional oncogenes. Furthermore, HIF-1α activity is commonly diminished by chromosomal deletion in ccRCCs, and increased HIF-1 activity reduces tumor burden in xenograft tumor models. Conversely, polymorphisms at the HIF-2α gene locus predispose to the development of ccRCCs, and HIF-2α promotes tumor growth. Genetic studies have revealed a prominent role for chromatin-modifying enzyme genes in ccRCC, and these may further modulate specific aspects of the HIF response. This suggests that, rather than global activation of HIF, specific components of the response are important in promoting kidney cancer. Some of these processes are already targets for current therapeutic strategies, and further dissection of this pathway might yield novel methods of treating RCC.

conclusionsIn contrast to many tumor types, HIF-1α and HIF-2α have opposing effects in ccRCC biology, with HIF-1α acting as a tumor suppressor and HIF-2α acting as an oncogene. The overall effect of VHL inactivation will depend on fine-tuning of the HIF response. PATIENT SUMMARY: High levels of hypoxia-inducible transcription factors (HIF) are particularly important in the clear cell type of kidney cancer, in which they are no longer properly regulated by the von Hippel-Lindau protein. The two HIF-α proteins have opposing effects on tumor evolution.

Indexed as

Tumor MicroenvironmentAnimalsBasic Helix-Loop-Helix ProteinsCarcinoma, Renal CellCell HypoxiaEndothelial PAS Domain-Containing Protein 1Gene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsOxygenPrognosisSignal TransductionUp-RegulationVon Hippel-Lindau Tumor Suppressor ProteinBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1HIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitOxygenVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinClear cell renal cell carcinomaHypoxiaHypoxia-inducible transcription factorsvon Hippel-Lindau

Identifiers

PMID26298207
PMCPMC5012644
OpenAlexW1759375471

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.